Serrated Polyps and a Classification of Colorectal Cancer

Transcription

1 Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011

2 Structure Serrated polyps and cancer Molecular biology The Jass classification

3 The familiar but oversimplified Vogelsteingram B Vogelstein et al, NEJM, 1988

4 The serrated neoplastic pathway Hyperplastic polyp Sessile serrated polyp Sessile serrated polyp with dysplasia (sessile serrated adenoma) Invasive adenocarcinoma

5

6

7 Serrated adenocarcinoma

8

9 Serrated polyps are often multiple Serrated carcinomas occur at two sites, the right side and the rectosigmoid Thought to represent at least 5-10% of all cancers

10 Schreiner MA et al. Gastroent, 2010 v139 p1497 Investigated detection of non-dysplastic serrated polyps at screening colonoscopy in 3,100 pts At baseline 7.9% of pts had at least one such polyp. Odds ratio for having a synchronous cancer was 1.9 ( ). If NDSP >10mm the OR rose to 3.4 ( ) During surveillance those with a baseline NDSP and no cancer were more likely to develop a metachronous tumour (OR 3.1, CI )

11 Molecular biology

12 Biological differences between the mucosa of the right and left colon What these are is currently not well understood. Variations in the expression of blood group antigens, acidic and neutral mucin, cytochrome P450 enzymes and the pro-apoptotic bcl-2 homologue bak have been described, as have differences in exposure to potentially pro-mutagenic bile acid metabolites (Iacopetta, B. (2002). "Are there two sides to colorectal cancer?" Int Cancer 101(5): 403-8)

13 Molecular genetic changes Hyperplastic polyps contain defined but variable genetic alterations Microsatellite instability in 9-68%, BRAF mutations in 46-76%, and KRAS mutations in 13-23% Sessile serrated polyps have MLH1 hypermethylation and BRAF mutations in most (>80%) but <10% contain KRAS mutations

14 Epigenetic hypermethylation of specific CpG groups (adding extra methyl side chains) is a common way of switching off expression of certain genes Hypermethylation

15 CpG island methylator phenotype CIMP (CpG island methylator phenotype) refers to promoter hypermethylation of a particular group of tumour suppressor genes including MLH1, p16, p14, MGMT (Omethylguanine methyltransferase), RASSF1 (Ras associated family) and TIMP3 (tissue inhibitor of metallopeptidase) This methylation is not a random process but occurs at certain common sequence motifs CIMP is strongly associated with BRAF mutations

16 BRAF mutations occur in 0% of tubular adenomas 19% of hyperplastic polyps 80% of SSAs 15% of all colon cancers

17 MLH1 and the mismatch repair complex repairs mismatches in repeat sequences of DNA

18 Genetic mutation vs somatic hypermethylation In HNPCC, microsatellite unstable tumours are caused by an inherited genetic mutation in either the MLH1 or MSH2 gene In sporadic microsatellite unstable tumours, there is hypermethylation of the MLH1 gene promoter. Hypermethylation is a common mechanism for regulating gene expression: increased promoter methylation leads to decreased gene expression

19 Hereditary non-polyposis colon cancer vs sporadic MSI-H cancer An autosomal dominant disorder with early onset of colorectal, endometrial, ovarian and urothelial carcinoma HNPCC is caused by mutations in the MLH1 or MSH2 genes at 3p and 2p respectively These genes code for two proteins in the DNA mismatch repair (MMR) system Sporadic MSI-H cancers comprise 8-12% of colorectal cancers and have a better prognosis than microsatellite stable (MSS) tumours

20 Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma Karolina Stefanius et al 2011 Histopathology 58,

21 Aims To define the occurrence of KRAS and BRAF mutations, microsatellite instability (MSI), and MGMT and hmlh1 methylation and expression in colorectal serrated adenocarcinoma

22 Materials and Methods 42 serrated AC and 59 non-serrated AC KRAS and BRAF mutations, MSI panel analysis, MSI IHC (MLH1 and MSH2), and MGMT and hmlh1 methylation status were compared

23 Microsatellite instability Mismatch repair (MMR) immunohistochemistry KRAS mutation analysis

24 Results BRAF and KRAS mutations did not coexist BRAF mutations present in 33% of serrated AC and no non-serrated AC KRAS mutations present in 45% of serrated AC and 27% of non-serrated AC (p=0.002)

25 Results MSI-H was seen in only 21% of serrated AC (7/34). Five BRAF and one KRAS mutations were observed in the 11 MSI-H tumours (and five were wild type) Four out of 59 non-serrated AC were MSI-H. In non-serrated AC MSI-H and KRAS mutations did not co-occur BRAF mutations were tightly associated with hmlh1 and MGMT methylation, whereas KRAS mutations had a negative correlation with methylation

26 Discussion Most serrated AC were in Jass groups 2 and 3, and most non-serrated AC were in Jass groups 3 and 4 Molecular groups 1-5 based on CIMP status and MSI status KRAS and BRAF mutations are very common (79%) in serrated AC. MSI-H was only seen in 21% So activation of the MAP kinase pathway is central to the serrated AC pathway

27 Discussion KRAS mutations have been considered characteristic of Vogelstein s adenoma to carcinoma model, but KRAS mutations are rare in tubular adenomas (~1-10%). But the Vogelstein model, published in 1990, may be contaminated by serrated adenomas which had not then been described The high frequency of KRAS mutations in serrated AC strengthens the importance of the serrated pathway % of KRAS mutated CRCs may evolve from serrated polyps KRAS mutated CRCs are insensitive to EGFR blocking therapies

28 The CRC neoplastic pathway Classical adenoma pathway (APC, SMAD4, p53) Invasive adenocarcinoma Hyperplastic polyp Sessile serrated polyp Sessile serrated polyp with dysplasia (BRAF or CIMP +/- MSI-H)

29 Classification of colorectal cancer based on correlation of clinical, morphological and molecular features Jass J. (2007) Histopathology, 50,

30 Molecular classification of colorectal cancer Molecular groups 1-5 based on CIMP status and MSI status CIMP high and MSI high (BRAF mutation and serrated polyp) 2 CIMP high and MSS (BRAF mutation and serrated polyp) 3 CIMP low and MSS (KRAS mutation: adenoma or SP) 4 CIMP negative and MSS (the bog standard cancer) 5 CIMP negative and MSI high (Lynch syndrome)

31 MSI status H S S S H Methylation /- +/- Ploidy Dip Dip An An Dip APC mutation KRAS mutation BRAF mutation p53 mutation +/- +/

32 Microsatellite instability Mismatch repair (MMR) immunohistochemistry KRAS mutation analysis

33 Anatomy and epidemiology Location R > L R > L L > R L > R R > L Gender F > M F > M M > F M > F M > F Precursor SP SP SP or Ad Ad Ad

34 Histology Serration /- +/- Mucinous Necrosis + +? Poorly Diff Lymphocytes +++ +? + +++

35 MSI creates proteins with slightly different epitopes that can stimulate an immune response as they are not recognised as self

36

37 The CRC neoplastic pathway Classical adenoma pathway (APC, SMAD4, p53) Invasive adenocarcinoma Hyperplastic polyp Sessile serrated polyp Sessile serrated polyp with dysplasia (BRAF or CIMP +/- MSI-H)

38 P47 Thunderbolt courtesy of John Nottingham, Northampton